AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23027677
Drug: Acute 1-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute 1-mg dose of alprazolam
Trial: 10210759
Drug: Moderate effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate effect of treatments
Trial: 8896514
Drug: B‐C7 (anti‐TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐C7 (anti‐TNF monoclonal antibody)
Trial: 6684468
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg X day‐1 for 5 consecutive days
Trial: 22936524
Drug: PDA, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA, daily tailored feedback messages (PDA + FB)
Trial: 22936524
Drug: PDA, no-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA, no-daily feedback
Trial: 22936524
Drug: paper diary
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paper diary (PD), no-daily feedback
Trial: 21976939
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) 80 mg orally, twice a day for four weeks
Trial: 21976939
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice a day for four weeks
Trial: 15875189
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin 100 IU day(‐1), 1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D
Trial: 15875189
Drug: Placebo (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D)
Trial: 11930591
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ribavirin and interferon alfa-2b
Trial: 31636243
Drug: 1 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg/kg dexmedetomidine plus local infiltration of 0.2 ml/kg bupivacaine 0.5% (BD)
Trial: 30298411
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) - two placebo tablets twice daily for 3 weeks
Trial: 19686477
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Trial: 19686477
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Trial: 17452505
Drug: Trandolapril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (4 mg per day)
Trial: 15054428
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg vitamin C
Trial: 15054428
Drug: 7500 mg
RxNorm normalized name: sodium sulfate 7500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7500 mg vitamin C
Trial: 7910089
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine with 69‐kd membrane protein (CP4)
Trial: 7910089
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine without 69‐kd membrane protein (CP5)
Trial: 7910089
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (CP4DT or CP5DT)
Trial: 7910089
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (CP5DT) for 4‐ to 6‐year‐old children
Trial: 3309829
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefotiam pre-operative antibioprophylaxis
Trial: 29872876
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha 2-a (PEG-IFN α-2a) therapy
Trial: 25822572
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 mL of methylprednisolone acetate, 40 mg/mL, dissolved in 4 mL of lidocaine hydrochloride, 10 mg/mL)
Trial: 25822572
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (1 mL isotonic saline mixed with 4 mL of lidocaine hydrochloride, 10 mg/mL)
Trial: 24430056
Drug: Lantoks injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lantoks injections in spastic muscles
Trial: 24430056
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (massage, exercise therapy, FTL, pharmacotherapy)
Trial: 10984564
Drug: Inactivated-poliovirus vaccine
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated-poliovirus vaccine (IPV), administered subcutaneously
Trial: 9076288
Drug: Letter of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letter of invitation for a flu vaccine
Trial: 9076288
Drug: Offer of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Offer of a free flu vaccine
Trial: 27816913
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture (4 joules/cm², total dose = 40 joules)
Trial: 23962386
Drug: Skin and
RxNorm normalized name: Hair Skin and Nails
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin and subcutaneous fat thickness
Trial: 7733122
Drug: Acarbose 200
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 200 mg
Trial: 20066964
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg with sucrose
Trial: 20066964
Drug: Acarbose 200
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 200 mg with sucrose
Trial: 15083524
Drug: Lorazepam (single-dose)
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam (single-dose)
Trial: 25670362
Drug: Anacetrapib 100
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100 mg/day
Trial: 16753373
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bicalutamide daily
Trial: 9829605
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) supplementation (0.15 mg/kg/d) during total parenteral nutrition (TPN)
Trial: 2688065
Drug: Sucralfate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4 g)
Trial: 2688065
Drug: Prednisolone metasulphobenzoate
RxNorm normalized name: prednisolone sodium metasulphobenzoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone metasulphobenzoate (20 mg)
Trial: 5310209
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg twice daily for 20 days)
Trial: 23389298
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (Gln)
Trial: 21778352
Drug: Gemfibrozil 30
RxNorm normalized name: gemfibrozil 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 30 mg
Trial: 21778352
Drug: Gemfibrozil 100
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 100 mg
Trial: 21778352
Drug: Gemfibrozil 300
RxNorm normalized name: gemfibrozil 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 300 mg
Trial: 21778352
Drug: Gemfibrozil 900
RxNorm normalized name: gemfibrozil 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 900 mg
Trial: 18623910
Drug: Recombinant parathyroid
RxNorm normalized name: Recombinant parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant parathyroid hormone
Trial: 16495253
Drug: FPV 1,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 1,400 mg BID plus RTV 100 mg BID
Trial: 16495253
Drug: FPV 1,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 1,400 mg BID plus RTV 200 mg BID
Trial: 16495253
Drug: FPV 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV 700 mg BID plus RTV 100 mg BID
Trial: 11482295
Drug: Computerized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized treatment simulation presentation
Trial: 11482295
Drug: Treatment simulation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment simulation group
Trial: 27230437
Drug: Real-time medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time medication monitoring (RTMM) with tailored SMS reminders
Trial: 22726281
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg once daily)
Trial: 22726281
Drug: Pregabalin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (75 mg twice daily)
Trial: 19473334
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration after mail administration
Trial: 19473334
Drug: Mail administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mail administration first
Trial: 19473334
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration first
Trial: 12476290
Drug: Alanyl-glutamine dipeptide
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl-glutamine dipeptide (30 g i.v. from day +1 to day +14)
Trial: 7599546
Drug: Morphine combined
RxNorm normalized name: morphine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine combined with bupivacaine injected into the knee joint
Trial: 31849085
Drug: Albumin infusion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin infusion (8 g/dL of ascitic fluid; n = 40)
Trial: 30884808
Drug: SAx (Hydroxytyrosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAx (Hydroxytyrosol 9.9 mg and Punicalagin 195 mg)
Trial: 15377355
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product (TCP) containing calcipotriol (50 microg g(‐1)) and betamethasone dipropionate (0.5 mg g(‐1)) applied once or twice daily
Trial: 15377355
Drug: Calcipotriol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (50 microg g(‐1)) applied twice daily
Trial: 15377355
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) applied twice daily
Trial: 15377355
Drug: TCP applied
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCP applied once daily
Trial: 15377355
Drug: Calcipotriol applied
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol applied twice daily
Trial: 15377355
Drug: TCP applied
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCP applied twice daily
Trial: 11409676
Drug: Complete implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete implant stabilised oral prostheses (IG)
Trial: 6685644
Drug: low-dose chemotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose chemotherapy (lmfp)
Trial: 24472854
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (n=1736)
Trial: 23350190
Drug: Ribavirin in
RxNorm normalized name: ribavirin Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin in combination with cycloferon
Trial: 15811981
Drug: 380 mg
RxNorm normalized name: aspirin 380 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 380 mg long-acting naltrexone
Trial: 15811981
Drug: 190 mg
RxNorm normalized name: papain 190 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 190 mg long-acting naltrexone
Trial: 8447208
Drug: Sufentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with neurolept analgesia
Trial: 8447208
Drug: Sufentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with halothane
Trial: 8447208
Drug: Sufentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with enflurane
Trial: 8447208
Drug: Sufentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (2 micrograms kg‐1 intravenous bolus) with isoflurane
Trial: 3961308
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of social, medical and psychological interventions
Trial: 27445550
Drug: IPPB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPPB therapy
Trial: 27445550
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IPPB and PEEP therapy
Trial: 27445550
Drug: PEEP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP therapy
Trial: 27445550
Drug: IPPB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPPB and PEEP therapy
Trial: 22510537
Drug: Behavioral physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral physical therapy interventions
Trial: 19092235
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg daily) + IPL therapy
Trial: 19092235
Drug: IPL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL therapy alone
Trial: 17251674
Drug: Geometric mean
RxNorm normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geometric mean of log minimum dose (Dmin) in CSA patients
Trial: 17251674
Drug: Geometric mean
RxNorm normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geometric mean of log minimum dose (Dmin) in CP patients
Trial: 17251674
Drug: Geometric mean
RxNorm normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (ROSA GEOMETRIC) - PINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geometric mean of log minimum dose (Dmin) in control subjects
Trial: 7968646
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol (E2) TTS 0.05 mg/day for 6 months and 0.025 mg/day for the following six months
Trial: 7968646
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol (E2) TTS 0.10 mg/day for the first 6 months and 0.05 mg/day for the following 6 months
Trial: 3112729
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (15 micrograms polysaccharide and 51 micrograms protein)
Trial: 26319483
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (1.0 mg/kg)
Trial: 23354394
Drug: Bitter orange
RxNorm normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter orange extract (approximately 49mg p-synephrine) plus naringin and hesperidin, twice daily for 60 days
Trial: 23354394
Drug: Bitter orange
RxNorm normalized name: BITTER ORANGE
DrugBank: Citrus aurantium fruit (DB16598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter orange extract (approximately 49mg p-synephrine) alone, twice daily for 60 days
Trial: 23354394
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 60 days
Trial: 16831092
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg JS2 DNA
Trial: 16831092
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg JS2 DNA
Trial: 16831092
Drug: JS2 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS2 DNA (both doses)
Trial: 10770766
Drug: Quinine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine at 10 mg/kg three times a day for 7 days (Q)
Trial: 10770766
Drug: Artemisinin at
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin at 20 mg/kg followed by quinine for 3 days (AQ3)
Trial: 10770766
Drug: Artemisinin at
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin at 20 mg/kg followed by quinine for 5 days (AQ5)
Trial: 9340504
Drug: Double-bolus alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-bolus alteplase (50 mg over 1-3 minutes followed by 50 mg 30 minutes later, or 40 mg for patients <60 kg)
Trial: 9340504
Drug: Accelerated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated infusion of alteplase (100 mg over 90 minutes)
Trial: 9340504
Drug: Accelerated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated infusion of alteplase
Trial: 3110981
Drug: misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 400 micrograms, twice daily for up to 8 weeks
Trial: 3110981
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg, twice daily for up to 8 weeks
Trial: 26963198
Drug: Non-pedicled buccal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pedicled buccal fat pad graft (BFPG)
Trial: 19213086
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg with closure device
Trial: 19213086
Drug: Enoxaparin 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.75 mg/kg with closure device
Trial: 19213086
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg with smaller sheath size (<7 Fr)
Trial: 19213086
Drug: Enoxaparin 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.75 mg/kg with smaller sheath size (<7 Fr)
Trial: 15111165
Drug: Heparin-coated circuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuit (group H)
Trial: 9153333
Drug: Scrotal system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scrotal system (Testoderm Testosterone Transdermal System) delivering approximately 4 mg testosterone over 24 hours
Trial: 9153333
Drug: Nonscrotal system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonscrotal system (Androderm Testosterone Transdermal System) providing approximately 5 mg testosterone over 24 hours
Trial: 24014884
Drug: 5-fluorouracil continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil continuous infusion (800 mg/m2/day, ci, d1-5, q4w)
Trial: 24014884
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and 5-fluorouracil therapy (methotrexate, 100 mg/m2, bolus infusion, followed 3 h later by 5-fluorouracil, 600 mg/m2, bolus infusion, with leucovorin rescue, q1w)
Trial: 18454257
Drug: Natural honey
RxNorm normalized name: Robitussin Cough Drop Herbal With Natural Honey Center
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural honey (70 g daily for 30 days)
Trial: 18454257
Drug: Sucrose (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (70 g daily for 30 days)